Alexandra S. Wolff, PharmD, BCOP

Alexandra S. Wolff, PharmD, BCOP, comments on her experience with CPX-351 in clinical practice and the potential to combine CPX-351 with targeted agents for AML.

Alexandra S. Wolff, PharmD, BCOP, explores the 5-year follow-up data from the phase 3 trial of CPX-351 in AML.

Expert continues discussion on important considerations for the optimal use if venetoclax in patients with AML, such as CYP3A4 and p-glycoprotein drug interactions.

Alexandra S. Wolff, PharmD, BCOP, highlights considerations for optimal use of venetoclax in patients with AML, such as tumor lysis syndrome prophylaxis.

Expert discusses the role of venetoclax in the treatment of AML and if achievement of MRD negativity can be used to predict long-term outcomes.

Expert continues discussion of IDH1 and IDH2 inhibitors in AML and examines prioritization of IDH1 and IDH2 inhibitors versus venetoclax in newly diagnosed AML.

Alexandra S. Wolff, PharmD, BCOP, discusses use of IDH1 and IDH2 inhibitors in newly diagnosed AML patients and highlights recently released trial data.

Expert examines the status of second-generation FLT3 inhibitors in newly diagnosed AML patients and the challenge with comparing clinical trial efficacy endpoints.

Expert discusses the role of FLT3 inhibitors in the treatment of AML and if benefit from midostaurin in combination with chemotherapy can be predicted.